RaQualia Pharma Inc
TSE:4579
Intrinsic Value
RaQualia Pharma, Inc. engages in a research and development of pharmaceuticals. [ Read More ]
The intrinsic value of one
RaQualia Pharma Inc
stock under the Base Case scenario is
1 341.44
JPY.
Compared to the current market price of 595 JPY,
RaQualia Pharma Inc
is
Undervalued by 56%.
RaQualia Pharma Inc's market capitalization is 12.9B JPY.
RaQualia Pharma Inc stock price is 595 JPY.
RaQualia Pharma Inc stock price (595 JPY) is 56% less than its Intrinsic Value (1 341.44 JPY).
RaQualia Pharma Inc stock price (595 JPY) is 74% less than its DCF Value (2 315.37 JPY). Open DCF Valuation
RaQualia Pharma Inc stock (367.5 JPY) is 38% less than its price (595 JPY). Open Relative Valuation
RaQualia Pharma Inc has upside potential of 209% compared to the average analyst price target.
Open Wall St Estimates
RaQualia Pharma Inc has negative Operating Income for the last twelve months.
RaQualia Pharma Inc has negative Net Income for the last twelve months.
RaQualia Pharma Inc's ROE (Return on Equity) has decreased in the last 3 years from -2% to -6%, and is approaching profitability.
RaQualia Pharma Inc has negative Free Cash Flow for the last twelve months.
RaQualia Pharma Inc has positive three-year average ROE (Return on Equity): 7%. The company is efficient at transforming stockholders' equity into net income.
RaQualia Pharma Inc has positive three-year average ROIC (Return on Invested Capital): 18%. The company is efficient at using invested capital to generate operating income.
RaQualia Pharma Inc's ROE (Return on Equity) for the past 12 months is negative and is equal to -6%.
RaQualia Pharma Inc's Revenue has been growing by 20% per year for the last 3 years.
RaQualia Pharma Inc's Revenue has dropped by 35% over the past 12 months.
RaQualia Pharma Inc's ROIC (Return on Invested Capital) has significantly decreased in the last 3 years from 45% to -14%.
RaQualia Pharma Inc's ROIC (Return on Invested Capital) for the past 12 months is negative and is equal to -14%.
RaQualia Pharma Inc has positive Gross Profit for the last twelve months.
RaQualia Pharma Inc's D/E (Debt to Equity) is very low and is equal to 0.05.
RaQualia Pharma Inc's short-term assets (5B JPY) exceed its short-term liabilties (389m JPY).
RaQualia Pharma Inc's long-term assets (7B JPY) exceed its long-term liabilties (752m JPY).
RaQualia Pharma Inc has negative Net Debt. This means that the company has more cash and short-term investments (4B JPY) than debt (291m JPY).
RaQualia Pharma Inc's Altman Z-Score is very high and is equal to 12.23.
RaQualia Pharma Inc doesn't generate enough operating income (-337m JPY) to safely cover interest payments on its debt (7m JPY).
Valuation Backtest
RaQualia Pharma Inc
Run backtest to discover the historical profit from buying and selling
RaQualia Pharma Inc
stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
RaQualia Pharma Inc
Balance Sheet Decomposition
RaQualia Pharma Inc
| Current Assets | 5B |
| Cash & Short-Term Investments | 3.8B |
| Receivables | 603.2m |
| Other Current Assets | 589m |
| Non-Current Assets | 1.9B |
| Long-Term Investments | 1.2B |
| PP&E | 573.6m |
| Intangibles | 30.2m |
| Other Non-Current Assets | 79.8m |
| Current Liabilities | 389.3m |
| Accounts Payable | 54.2m |
| Accrued Liabilities | 54.2m |
| Other Current Liabilities | 280.9m |
| Non-Current Liabilities | 362.2m |
| Long-Term Debt | 290.8m |
| Other Non-Current Liabilities | 71.4m |
Earnings Waterfall
RaQualia Pharma Inc
|
Revenue
|
1.9B
JPY
|
|
Cost of Revenue
|
-245.1m
JPY
|
|
Gross Profit
|
1.7B
JPY
|
|
Operating Expenses
|
-2B
JPY
|
|
Operating Income
|
-337.4m
JPY
|
|
Other Expenses
|
13.7m
JPY
|
|
Net Income
|
-323.7m
JPY
|
Free Cash Flow Analysis
RaQualia Pharma Inc
Profitability Score
Profitability Due Diligence
RaQualia Pharma Inc's profitability score is 49/100. The higher the profitability score, the more profitable the company is.
Score
RaQualia Pharma Inc's profitability score is 49/100. The higher the profitability score, the more profitable the company is.
Solvency Score
Solvency Due Diligence
RaQualia Pharma Inc's solvency score is 75/100. The higher the solvency score, the more solvent the company is.
Score
RaQualia Pharma Inc's solvency score is 75/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
Price Targets Summary
RaQualia Pharma Inc
According to Wall Street analysts, the average 1-year price target for
RaQualia Pharma Inc
is 1 836 JPY
with a low forecast of 1 818 JPY and a high forecast of 1 890 JPY.
Shareholder Return
Price
RaQualia Pharma Inc
| Average Annual Return | -7.73% |
| Standard Deviation of Annual Returns | 12.96% |
| Max Drawdown | -65% |
| Market Capitalization | 12.9B JPY |
| Shares Outstanding | 21 623 250 |
| Percentage of Shares Shorted |
N/A
|
Company Profile
RaQualia Pharma Inc
Country
Industry
Market Cap
Dividend Yield
Description
RaQualia Pharma, Inc. engages in a research and development of pharmaceuticals. The company is headquartered in Nagoya, Aichi-Ken and currently employs 67 full-time employees. The company went IPO on 2011-07-20. The firm is mainly engaged in the discovery and research, the preclinical trials and part of clinical trials of drugs, as well as the licensing of developed compounds to pharmaceutical companies. The firm is focused on pain diseases area and intestinal disease area. Its products include EP4 antagonist, cyclooxygenase-2 (COX-2) inhibitory, 5-HT4 portion partial agonist, among others.
Contact
IPO
Employees
Officers
The intrinsic value of one
RaQualia Pharma Inc
stock under the Base Case scenario is
1 341.44
JPY.
Compared to the current market price of 595 JPY,
RaQualia Pharma Inc
is
Undervalued by 56%.
You don't have any saved screeners yet
